We present real-world data on all ruxolitinib-treated myelofibrosis patients in a 10-million-resident region, with a follow-up of 2 years.We found no evidence of an increased risk of developing lymphomas.
Second primary malignancies in ruxolitinib-treated myelofibrosis : real-world evidence from 219 consecutive patients / M. Maffioli, T. Giorgino, B. Mora, A. Iurlo, E. Elli, M.C. Finazzi, M. Caramella, E. Rumi, M.C. Carraro, N. Polverelli, M. D'Adda, S. Malato, M. Rossi, A. Molteni, A. Vismara, C. Sissa, F. Spina, M. Anghilieri, D. Cattaneo, R. Renso, M. Bellini, M.L. Pioltelli, C. Cavalloni, D. Barraco, R. Accetta, L. Bertu, M.G.D. Porta, F. Passamonti. - In: BLOOD ADVANCES. - ISSN 2473-9529. - 3:21(2019 Nov), pp. 3196-3200.
Second primary malignancies in ruxolitinib-treated myelofibrosis : real-world evidence from 219 consecutive patients
M.C. Finazzi;M. Caramella;D. Cattaneo;R. Accetta;F. Passamonti
2019
Abstract
We present real-world data on all ruxolitinib-treated myelofibrosis patients in a 10-million-resident region, with a follow-up of 2 years.We found no evidence of an increased risk of developing lymphomas.
| File | Dimensione | Formato | |
|---|---|---|---|
|
advancesadv2019000646.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
722.7 kB
Formato
Adobe PDF
|
722.7 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
